Invesco’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Invesco’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-904	Closed	-$6K	–	4124
2015 Q2	$6K	Buy	+904	New	+$7K	﹤0.01%	4156

Other funds holding GNMX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's GNMX Position: Q3 2015 in Review

Invesco sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2015, closing a stake of 904 shares — an estimated $6K sold.

Invesco first reported a position in GNMX in Q2 2015 and held it in 1 quarter. The position peaked at $6K in Q2 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q3 2015.

Invesco reported no remaining Aevi Genomic Medicine Inc position as of Q3 2015 after selling out during the quarter.
Invesco sold 904 Aevi Genomic Medicine Inc shares in Q3 2015, an estimated $6K.
Invesco first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 1 quarter.
Invesco's Aevi Genomic Medicine Inc position peaked at $6K in Q2 2015.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2015.

Based on Invesco's 13F filing for Q3 2015, filed 16 Nov 2015.